|
|
|
|
| LEADER |
01000naa a22002652c 4500 |
| 001 |
NLM392736772 |
| 003 |
DE-627 |
| 005 |
20250920232035.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
250920s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202501526
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1574.xml
|
| 035 |
|
|
|a (DE-627)NLM392736772
|
| 035 |
|
|
|a (NLM)40557485
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chronopoulos, Antonios
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.09.2025
|
| 500 |
|
|
|a Date Revised 19.09.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2025 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Neuroblastoma (NB), the most common extracranial solid tumor in children, exhibits intra-tumoral heterogeneity with two interconvertible identities: adrenergic (ADRN) and mesenchymal (MES). Compared to ADRN cells, MES cells exhibit phenotypes associated with metastasis and therapy resistance. Thus, the transition from ADRN to MES may contribute to poor clinical outcomes, necessitating further investigation into this ADRN-to-MES transition (AMT) to improve clinical responses. The extracellular matrix (ECM), a critical component of the tumor microenvironment (TME), provides structural support and delivers mechanical signals that influence oncogenic processes. This research demonstrates that high-risk NB tumors contain more topographically aligned ECM fibers than low-risk NB tumors. Using nano-fabricated biomaterials designed to mimic the aligned ECM, ECM topography is revealed to drive AMT through transcriptional and epigenetic changes, accompanied by enhanced MES phenotypic features. Furthermore, ECM topography is shown to stimulate Rho-associated kinase and YAP signaling pathways, which mediate ECM-driven reprogramming. These findings introduce ECM-driven AMT as a novel mechanism in NB progression and provide insights into TME-targeted therapeutic strategies aimed at suppressing MES cells to improve clinical outcomes in NB
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a YAP
|
| 650 |
|
4 |
|a adrenergic to mesenchymal transition
|
| 650 |
|
4 |
|a extracellular matrix
|
| 650 |
|
4 |
|a neuroblastoma
|
| 650 |
|
4 |
|a rho‐kinase
|
| 650 |
|
7 |
|a rho-Associated Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a Biocompatible Materials
|2 NLM
|
| 700 |
1 |
|
|a Vemula, Chandra Kaladhar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zamloot, Vic
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chavez, Ivan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kennedy, Rebekah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Woochan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bell, Devon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Yuanzhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moghimi, Babak
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Jangho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Asgharzadeh, Shahab
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, JinSeok
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 37(2025), 37 vom: 24. Sept., Seite e2501526
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:37
|g year:2025
|g number:37
|g day:24
|g month:09
|g pages:e2501526
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202501526
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 37
|j 2025
|e 37
|b 24
|c 09
|h e2501526
|